"Is Prime Editing Ready for Mainstream Use?"

Prime editing, an advanced form of CRISPR/Cas9 technology, has received FDA approval for its first clinical trial by Prime Medicine to treat chronic granulomatous disease (CGD). This technology, which can correct up to 89% of known genetic variants, offers precise and versatile genome editing capabilities. While promising for treating various genetic disorders, challenges remain in terms of design, delivery, safety, and high manufacturing costs.